FDA mandates GLP-1 labels warn of rare blindness risk NAION

The US FDA has ordered manufacturers of GLP-1 drugs (Ozempic, Wegovy) to add label warnings about NAION, a rare eye condition that can cause blindness. This follows accumulating evidence linking the drugs to the condition, though causality remains uncertain. The regulatory action could affect prescribing patterns and litigation risk for the drugmakers.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works